{'52WeekChange': -0.44765842,
 'SandP52WeekChange': 0.0644362,
 'address1': '22 Boston Wharf Road',
 'address2': '9th Floor',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 12.04,
 'askSize': 1800,
 'averageDailyVolume10Day': 201337,
 'averageVolume': 286898,
 'averageVolume10days': 201337,
 'beta': 1.21321,
 'beta3Year': None,
 'bid': 10.01,
 'bidSize': 1100,
 'bookValue': 5.029,
 'category': None,
 'circulatingSupply': None,
 'city': 'Boston',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 12.6,
 'dayLow': 11.99,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -30.526,
 'enterpriseToRevenue': 2.393,
 'enterpriseValue': 815628928,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 13.886429,
 'fiftyTwoWeekHigh': 23.98,
 'fiftyTwoWeekLow': 8,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 17676816,
 'forwardEps': -1.96,
 'forwardPE': -6.137755,
 'fromCurrency': None,
 'fullTimeEmployees': 294,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.82877,
 'heldPercentInstitutions': 0.20842,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/akceatx.com',
 'longBusinessSummary': 'Akcea Therapeutics, Inc., a biopharmaceutical '
                        'company, focuses on developing and commercializing '
                        'medicines to treat patients with serious and rare '
                        'diseases in the United States and internationally. '
                        'The company offers TEGSEDI, an antisense medicine '
                        'designed to reduce the production of transthyretin '
                        'protein. It develops WAYLIVRA, which has completed '
                        'Phase III clinical study for the treatment of '
                        'familial chylomicronemia syndrome, as well as is in '
                        'Phase III clinical study for the treatment of '
                        'familial partial lipodystrophy. The company also '
                        'develops AKCEA-APO(a)-LRx, which has completed Phase '
                        'IIb clinical study for treating hyperlipoproteinemia; '
                        'AKCEA-ANGPTL3-LRx that has completed Phase IIb '
                        'clinical study for the treatment of homozygous '
                        'familial hypercholesterolemia; and AKCEA-APOCIII-LRx, '
                        'which is in Phase II study for the treatment of '
                        'cardiovascular disease due to elevated triglyceride '
                        'levels, as well as AKCEA-TTR-LRx to treat the broad '
                        'population of patients with hereditary and wild-type '
                        'forms of transthyretin amyloidosis. It has strategic '
                        'collaboration with Novartis Pharma AG and PTC '
                        'Therapeutics International Limited. The company was '
                        'incorporated in 2014 and is headquartered in Boston, '
                        'Massachusetts. Akcea Therapeutics, Inc. is a '
                        'subsidiary of Ionis Pharmaceuticals, Inc.',
 'longName': 'Akcea Therapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 1221153280,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_306140818',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -42757000,
 'nextFiscalYearEnd': 1640908800,
 'open': 12.6,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.09,
 'phone': '617 207 0202',
 'previousClose': 12.79,
 'priceHint': 2,
 'priceToBook': 2.3921256,
 'priceToSalesTrailing12Months': 3.583186,
 'profitMargins': -0.08587,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 12.6,
 'regularMarketDayLow': 11.99,
 'regularMarketOpen': 12.6,
 'regularMarketPreviousClose': 12.79,
 'regularMarketPrice': 12.6,
 'regularMarketVolume': 223694,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 101509000,
 'sharesPercentSharesOut': 0.0306,
 'sharesShort': 3103299,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 3160662,
 'shortName': 'Akcea Therapeutics, Inc.',
 'shortPercentOfFloat': 0.246,
 'shortRatio': 7.52,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'AKCA',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.448,
 'twoHundredDayAverage': 15.549424,
 'volume': 223694,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.akceatx.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02210'}